Physician profile
Manan B Shah
NPI 1457548513
$8,388.68
in general payments reported to CMS, 2019-2025
42 companies · $836 in 2025
The $836 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,187 · 2020: $863 · 2021: $1,273 · 2022: $1,371 · 2023: $930 · 2024: $929 · 2025: $836.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,695.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,694.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,517.38 | 2019-2025 | Skyrizi, Rinvoq, Linzess |
| Boston Scientific Corporation | $1,210.53 | 2019-2025 | General - Therapies, Exalt Model D |
| Medtronic, INC. | $935.80 | 2021-2025 | Gi Genius, Endoflip |
| Ambu INC. | $635.34 | 2020-2024 | |
| Covidien LP | $511.87 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $413.29 | 2019-2025 | Xifaxan |
| Cook Medical LLC | $312.23 | 2019-2024 | Hemospray |
| Takeda Pharmaceuticals U.S.A., INC. | $298.32 | 2019-2025 | Entyvio |
| Merck Sharp & Dohme LLC | $247.95 | 2019-2024 | Dificid |
| Celgene Corporation | $221.04 | 2019-2023 | Zeposia |
| Amgen INC. | $214.83 | 2021-2022 | |
| Janssen Biotech, INC. | $205.37 | 2019-2025 | Tremfya, Stelara, Remicade |
| Intra-Sana Laboratories | $171.72 | 2025 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
| Genzyme Corporation | $168.58 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $158.76 | 2022-2025 | Dupixent |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $137.34 | 2024-2025 | Rezdiffra, Resmetirom |
| Harrow Eye, LLC | $131.54 | 2024 | |
| Ironwood Pharmaceuticals, INC | $120.54 | 2019-2021 | |
| Erbe USA INC | $110.02 | 2019 | |
| Nestle Healthcare Nutrition INC. | $73.78 | 2021-2022 | |
| Allergan, INC. | $64.37 | 2019 | |
| Olympus America INC. | $58.63 | 2020-2024 | Evis Exera III Colonovideoscope |
| Redhill Biopharma INC. | $44.41 | 2020-2022 | |
| Pfizer INC. | $41.53 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $41.17 | 2023 | Cyltezo |
| Organon LLC | $36.44 | 2021-2023 | Renflexis |
| Lilly USA, LLC | $33.66 | 2024-2025 | Omvoh |
| Qol Medical, LLC | $33.48 | 2019-2021 | |
| Braintree Laboratories, INC. | $29.65 | 2019-2022 | |
| Sandoz INC. | $21.96 | 2023 | Hyrimoz |
| Biocon Biologics INC | $21.57 | 2025 | Yesintek |
| Ardelyx, INC. | $19.72 | 2025 | Ibsrela |
| Seapearl East, INC | $19.54 | 2025 | |
| Blueprint Medicines Corporation | $17.78 | 2023 | |
| Evoke Pharma, INC. | $17.67 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $17.23 | 2021 | |
| Novo Nordisk INC | $17.06 | 2025 | |
| Intercept Pharmaceuticals, INC. | $15.11 | 2022 | |
| Micro-Tech Endoscopy USA, INC. | $14.18 | 2021 | |
| Eisai INC. | $13.84 | 2019 | |
| Ucb, INC. | $13.45 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manan Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.